Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bromocriptine for refractory rheumatoid arthritis]

R Mader1

  • 1Rheumatic Disease Unit, HaEmek Medical Center, Afula.

Harefuah
|February 6, 1998
PubMed
Summary

Bromocriptine (BRC), a prolactin (PRL) suppressor, showed potential in treating refractory rheumatoid arthritis (RA). Some patients experienced joint symptom improvement, suggesting BRC may benefit certain RA cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OASIS evaluation of the French surveillance network for antimicrobial resistance in diseased animals (RESAPATH): success factors underpinning a well-performing voluntary system.

Epidemiology and infection·2021
Same author

Applied precision cancer medicine in metastatic biliary tract cancer.

Hepatology international·2020
Same author

Abdominal fat distribution in diffuse idiopathic skeletal hyperostosis and ankylosing spondylitis patients compared to controls.

Clinical radiology·2018
Same author

Determination of Hydrogen Density by Swift Heavy Ions.

Physical review letters·2017
Same author

Role of computer-assisted surgery in osteotomies around the knee.

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA·2016
Same author

Long-term outcomes of tension band wiring with a single K-wire in Rockwood type IV/V acute acromio-clavicular dislocations: 25 cases.

Orthopaedics & traumatology, surgery & research : OTSR·2016

Area of Science:

  • Immunology
  • Rheumatology
  • Endocrinology

Background:

  • Prolactin (PRL) is increasingly recognized as an immunomodulator in autoimmune diseases.
  • Bromocriptine (BRC), a dopamine agonist, effectively suppresses PRL secretion.
  • Previous studies suggest BRC efficacy in psoriatic arthritis, Reiter's syndrome, and systemic lupus erythematosus.

Purpose of the Study:

  • To investigate the efficacy of Bromocriptine (BRC) in patients with refractory rheumatoid arthritis (RA).
  • To assess the clinical response and disease activity changes in RA patients treated with BRC.

Main Methods:

  • A small cohort of 5 patients with refractory RA, unresponsive to at least two disease-modifying antirheumatic drugs, received 5 mg of BRC nightly.
  • Patients were monitored for 6 months with assessments every 4-6 weeks.
  • Disease activity was evaluated based on joint counts and other relevant measures.

Main Results:

  • Three out of five patients demonstrated over 25% improvement in tender and swollen joint counts at 12 weeks.
  • Sustained improvement was observed in only two patients by the end of the 6-month study period.
  • No significant changes were noted in other disease activity markers, and one patient withdrew due to disease exacerbation.

Conclusions:

  • Bromocriptine (BRC) may offer potential benefits for a subset of patients with refractory rheumatoid arthritis (RA).
  • Further research with larger patient groups and varied dosages is warranted to fully elucidate BRC's role in RA treatment.
  • No correlation was found between serum PRL levels and disease activity in this study.

Related Experiment Videos